These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 196168

  • 1. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].
    Haacke H, Parwaresch MR, Mäder C.
    Med Klin; 1977 Jul 08; 72(27):1183-7. PubMed ID: 196168
    [Abstract] [Full Text] [Related]

  • 2. [Xantinol-nicotinate in primary type-V hyperlipoproteinaemia (author's transl)].
    Haacke H, Parwaresch MR, Mäder C.
    Dtsch Med Wochenschr; 1976 Sep 24; 101(39):1413-7. PubMed ID: 185036
    [Abstract] [Full Text] [Related]

  • 3. [The effect of xanthinol nicotinate on the serum lipids and lipoproteins of patients with primary hyperlipoproteinemia Type IIb and IV].
    Haacke H, Parwaresch MR, Mäder C.
    Verh Dtsch Ges Inn Med; 1976 Sep 24; 82 Pt 1():829-32. PubMed ID: 1029294
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Sep 24; 33(5):776-9. PubMed ID: 6683558
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T, Nakai T, Yamada S, Kobayashi T, Hayashi T, Kutsumi Y, Takeda R.
    Artery; 1979 Feb 24; 5(2):125-43. PubMed ID: 231951
    [Abstract] [Full Text] [Related]

  • 8. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia].
    Sauvanet JP, Drouin P, Mejean L, Lambert D, Debry G.
    Therapie; 1978 Feb 24; 33(5):615-22. PubMed ID: 217121
    [No Abstract] [Full Text] [Related]

  • 9. [Long-term treatment of hyperlipoproteinaemia, types IIa and IIb, with etiroxate (author's transl)].
    Schwartzkopff W, Russ E.
    Dtsch Med Wochenschr; 1975 Apr 11; 100(15):815-21. PubMed ID: 164334
    [Abstract] [Full Text] [Related]

  • 10. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
    Jung W, Kremer GJ, Müller D.
    MMW Munch Med Wochenschr; 1975 Oct 31; 117(44):1783-6. PubMed ID: 171564
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR, Klemens UH, Vollmar LJ, Lang PD.
    Med Klin; 1978 Dec 08; 73(49):1731-7. PubMed ID: 723760
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serum profile of non-esterified fatty acids (NEFA) in patients with hyperlipoproteinemia under xantinol--nicotinate (XN) medication.
    Haacke H, Parwaresch MR, Mäder C.
    Atherosclerosis; 1980 Sep 08; 37(1):77-85. PubMed ID: 7426090
    [Abstract] [Full Text] [Related]

  • 15. [Therapy of primary hyperlipoproteinemia types IIa, IIb and IV using beta pyridylcarbinol Study on three phases under ambulatory conditions].
    Klemens UH, von Löwis P.
    Dtsch Med Wochenschr; 1973 Jun 15; 98(24):1197-202. PubMed ID: 4350685
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J, Sauvanet JP, Chanu B, Bakir R, Goy-Loeper J, Saya C, Pinaroli F.
    Nouv Presse Med; 1980 Dec 22; 9(49):3747-51. PubMed ID: 7208341
    [Abstract] [Full Text] [Related]

  • 18. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
    Rouffy J, Dreux C, Goussault Y, Dakkak R, Renson FJ.
    Arzneimittelforschung; 1976 Dec 22; 26(5):901-6. PubMed ID: 183788
    [Abstract] [Full Text] [Related]

  • 19. [Effect of the lipid-lowering agent, procetofen, on the makeup of human biliary lipids].
    Grandjean EM, Mordasini R, Paumgartner G.
    Schweiz Med Wochenschr; 1979 Apr 21; 109(16):601-2. PubMed ID: 219470
    [Abstract] [Full Text] [Related]

  • 20. [Comparative studies of the lipid-lowering activity of etiroxate hydrochloride and dextrothyroxine (author's transl)].
    Schwartzkopff W, Russ E.
    MMW Munch Med Wochenschr; 1975 May 09; 117(19):827-30. PubMed ID: 805950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.